McKesson Corporation (MCK)
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Buy, Hold or Sell MCK Stock Following Robust Q3 Earnings?
McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the third quarter of fiscal 2025 despite ongoing macroeconomic challenges. The company also raised its full-year guidance.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
MCK Stock Down on Q3 Earnings & Sales Miss, Gross Margin Contracts
McKesson's third-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
McKesson Corporation (MCK) Q3 2025 Earnings Call Transcript
McKesson Corporation. (NYSE:MCK ) Q3 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Rachel Rodriguez - VP of Investor Relations Brian Tyler - Chief Executive Officer Britt Vitalone - Executive Vice President and Chief Financial Officer Conference Call Participants Eric Percher - Nephron Research Kevin Caliendo - UBS Allen Lutz - Bank of America Brian Tanquilut - Jefferies Lisa Gill - JPMorgan Stephen Baxter - Wells Fargo Erin Wright - Morgan Stanley George Hill - Deutsche Bank Daniel Grosslight - Citi Operator Welcome to McKesson's Third Quarter Fiscal 2025 Earnings Conference Call.
Here's What Key Metrics Tell Us About McKesson (MCK) Q3 Earnings
While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
McKesson (MCK) Q3 Earnings and Revenues Miss Estimates
McKesson (MCK) came out with quarterly earnings of $8.03 per share, missing the Zacks Consensus Estimate of $8.04 per share. This compares to earnings of $7.74 per share a year ago.
McKesson misses third-quarter revenue estimates
Drug distributor McKesson missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its U.S. pharmaceutical segment, which includes branded and specialty drugs.
McKesson Exceeds EPS, Q3 Profit Surges
Healthcare distribution and services specialist McKesson (MCK 0.59%) reported mixed financial results for fiscal 2025's third quarter on Wednesday, Feb. 5. McKesson beat earnings expectations with an adjusted EPS of $8.03, coming in just ahead of the projected $8.01.
McKesson Stock May Rise With PRISM Vision Holdings Acquisition
MCK is set to acquire a controlling stake in PRISM Vision Holdings, aiming to expand its specialty care capabilities and strengthen its leadership in eye health solutions across the United States.
MCK Stock Before Q3 Earnings: A Smart Buy or Risky Investment?
McKesson's third-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
McKesson (MCK) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, McKesson (MCK) stood at $594.75, denoting a -1.63% change from the preceding trading day.
